1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Fast Market Research Logo

New market study, "Abbott Laboratories: Company Analysis", has been published

New Pharmaceuticals market report from Datamonitor: "Abbott Laboratories: Company Analysis"

 
PRLog - Oct. 18, 2012 - This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Scope
* Gain insight into Abbott's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Abbott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Reasons to Get this Report
* Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector
* Examine how the spun out pharmaceuticals company Abbvie will fare as a standalone unit
* Discover how Abbott has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/464832_abbott_laboratories_com...
------------------------------------------------------------

Report Table of Contents:

Abbott Laboratories: Company Analysis
SCOPE OF ABBOTT ANALYSIS

* PharmaVitae Explorer database
* Analysis structure

* Executive summary
* Strategic insight
* Company overview
* Operating performance analysis

* Data sourcing

* Analyst consensus

EXECUTIVE SUMMARY

* Key findings
* Abbott prescription pharmaceutical sales outlook
* Abbott financial outlook
* SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

STRATEGIC INSIGHT

* Launch/core/expiry analysis
* M&A dictates Abbott's corporate strategy in run-up to AbbVie separation

* Indian market expansion

* Abbott has the leading share of the lucrative autoimmune disorder market

* Abbott's heavy reliance on Humira continues

* Weak pipeline undermines growth expectations
* Innovative pharma split imminent

COMPANY OVERVIEW

* Key findings
* Background
* Corporate structure

* Pharmaceuticals
* Nutritionals
* Diagnostics
* Vascular
* Other

* M&A history

* M&A strategy

OPERATING PERFORMANCE ANALYSIS

* Key findings
* Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005-11
* Operating costs and profit analysis

* Operating costs and profit analysis, 2005-11
* Operating cost and profit analysis, 2011-17

APPENDIX

* Exchange rates

TABLES

* Table: Datamonitor's established pharmaceutical company coverage, 2012
* Table: Abbott - key product overview ($m), 2011-17
* Table: Abbott's financial performance ($m), 2011-17
* Table: Abbott launch, core, and expiry portfolio overview ($m), 2011-17
* Table: AbbVie product portfolio sales ($m), 2011-17
* Table: AbbVie operating performance ($m), 2011-17
* Table: Abbott key merger and acquisition deals, 2001-11
* Table: Total Abbott sales by business unit ($m), 2005-11
* Table: Abbott operating revenue/cost analysis ($m), 2005-11
* Table: Abbott operating cost ratio analysis (percentage of total revenues), 2005-11
* Table: Abbott operating revenue/cost analysis ($m), 2011-17
* Table: Abbott operating cost ratio analysis (percentage of total revenues), 2011-17
* Table: Exchange rates, 2012

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: Abbott's prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005-17
* Figure: Abbott's financial performance ($m), 2005-17
* Figure: Abbott launch/core/expiry configuration ($m), 2011-17
* Figure: Leading companies in the immunology and inflammation biologics space (%), 2005-17
* Figure: Abbott operating revenue/cost analysis ($m), 2005-17

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research, Inc.
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical
Tags:abbott, 2011-17, pharmaceutical
Shortcut:prlog.org/11997046
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share